ArticleJournal of robotic surgery2025
Transoral robotic surgery for salivary carcinomas of the base of tongue: a multicenter REFCOR study.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A comparative analysis of transoral laser microsurgery and transoral robotic surgery for the treatment of oropharyngeal squamous cell carcinoma.Journal of robotic surgery · 2026Pooled it
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transoral robotic surgery (TORS) allows minimally invasive surgical access to the oropharynx. Its benefits are well documented for squamous cell carcinomas, but not for salivary carcinomas. The aim of this study was to describe the French experience of TORS regarding salivary gland carcinomas of the base of tongue (BOT). This was a retrospective multicentric study with a national cohort. We included all patients treated surgically for a BOT salivary gland carcinoma from January 2009 to December 2018. Descriptive analyses were performed. Among the 50 patients included, radical excision was performed through an open approach (OA; n = 33) or using TORS (n = 17). T1-T2 tumors were more common in the TORS-group (76.4% vs 60.6%), and so were low-grade tumors (58.8% vs 38.7%). Surgical margins were <1mm in 46.7% of patients in the TORS-group and 52% of patients in the OA-group. After 51.7 months of follow-up, two patients (11.8%) presented with a local recurrence in the TORS-group, versus eight patients (24.2%) in the OA-group. The rate of tracheostomy was 41.2% in the TORS-group and 63.6% in the OA-group. The rate of gastrostomy was 11.8% in the TORS-group and 36.4% in the OA-group. TORS is an acceptable minimally invasive option for selected BOT salivary carcinomas. It may provide good functional and oncological outcomes in selected cases, despite a high rate of close margins.
Indexed as
Identifiers
40234274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.